子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 植物来源“汤剂体”的提取和“本草体”的人工制备及其相关产品 | CN201980023065.9 | 2019-03-05 | CN111971072A | 2020-11-20 | 蒋澄宇; 李晓芸; 杜涧超; 梁竹; 王志清; 王晨轩 |
| 提供制备本草体的方法，包括以下步骤：将一种或多种脂质成分和/或与下列任一项或多项混合：核酸，化合物，大分子；和对所得的混合物进行加热处理。还提供从植物提取汤剂体的方法，包括以下步骤：用溶剂制备所述植物的提取液；对所述提取液进行差速离心；用水性溶液重悬所述沉淀物，以提供汤剂体。 | ||||||
| 2 | 抗氧化剂 | CN200680013301.1 | 2006-03-21 | CN101163659B | 2012-09-05 | T·鲁道夫; H·巴克霍尔兹 |
| 本发明涉及具有在说明书中定义的基团的式(I)化合物作为抗氧化剂的用途，涉及相应的新型组合物和组合物，而且涉及相应的制备化合物和组合物的方法。 | ||||||
| 3 | 植物来源“汤剂体”的提取和“本草体”的人工制备及其相关产品 | CN201980023065.9 | 2019-03-05 | CN111971072B | 2023-06-13 | 蒋澄宇; 李晓芸; 杜涧超; 梁竹; 王志清; 王晨轩 |
| 提供制备本草体的方法，包括以下步骤：将一种或多种脂质成分和/或与下列任一项或多项混合：核酸，化合物，大分子；和对所得的混合物进行加热处理。还提供从植物提取汤剂体的方法，包括以下步骤：用溶剂制备所述植物的提取液；对所述提取液进行差速离心；用水性溶液重悬所述沉淀物，以提供汤剂体。 | ||||||
| 4 | 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品 | CN201980023092.6 | 2019-03-28 | CN111918858B | 2023-03-21 | 蒋澄宇; 李晓芸; 杜涧超; 梁竹; 王志清; 王晨轩 |
| 涉及从中药中提取多种能够促进核酸递送的化合物或合成的化合物，并利用所提取的化合物或多种组合促进核酸如sRNA吸收和进入靶细胞中，并能促进核酸进入有此需要的对象体内的靶部位；所述中药选自红景天、蒲公英、穿心莲和金银花中药饮片；所述核酸用于治疗疾病，例如心脏、脾、肾、胃、肺和/或肠疾病。 | ||||||
| 5 | 脂质在制备核酸递送试剂中的应用及其相关产品 | CN202080077628.5 | 2020-11-08 | CN114650982A | 2022-06-21 | 蒋澄宇; 秦宇豪; 李晓芸; 张聪 |
| 通过一种或多种脂质化合物递送核酸的用途,以及包含所述脂质化合物和核酸的脂质核酸混合物、药物组合物或试剂盒。所提供的脂质化合物能够促进核酸的吸收，特别是口服吸收，以及促进核酸进入有此需要的对象体内的靶部位。 | ||||||
| 6 | 用于递送活性剂的可生物降解脂质 | CN201980077559.5 | 2019-09-27 | CN113164379A | 2021-07-23 | 穆图萨米·贾亚拉曼; 何果; 马丁·迈尔 |
| 本发明涉及阳离子脂质，该阳离子脂质具有位于该阳离子脂质的脂质部分(例如疏水链)中的一个或多个可生物降解基团。可以将这些阳离子脂质掺入到脂质颗粒中用于递送活性剂，例如核酸。本发明还涉及脂质颗粒，这些脂质颗粒包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质、以及任选地固醇。该脂质颗粒可以进一步包含治疗剂，例如核酸。 | ||||||
| 7 | 抗氧化剂 | CN200680013301.1 | 2006-03-21 | CN101163659A | 2008-04-16 | T·鲁道夫; H·巴克霍尔兹 |
| 本发明涉及具有在说明书中定义的基团的式(I)化合物作为抗氧化剂的用途，涉及相应的新型组合物和组合物，而且涉及相应的制备化合物和组合物的方法。 | ||||||
| 8 | 用于递送活性剂的可生物降解脂质 | CN201980077559.5 | 2019-09-27 | CN113164379B | 2024-04-16 | 穆图萨米·贾亚拉曼; 何果; 马丁·迈尔 |
| 本发明涉及阳离子脂质，该阳离子脂质具有位于该阳离子脂质的脂质部分(例如疏水链)中的一个或多个可生物降解基团。可以将这些阳离子脂质掺入到脂质颗粒中用于递送活性剂，例如核酸。本发明还涉及脂质颗粒，这些脂质颗粒包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质、以及任选地固醇。该脂质颗粒可以进一步包含治疗剂，例如核酸。#imgabs0# | ||||||
| 9 | FA类脂质化合物在制备核酸递送试剂中的应用及其相关产品 | CN202280052440.4 | 2022-07-27 | CN117794894A | 2024-03-29 | 蒋澄宇; 马一鸣; 徐龙鑫 |
| 一种或多种脂质化合物递送核酸的用途，以及包含所述脂质化合物和核酸的脂质核酸混合物、药物组合物或试剂盒。以上提供的脂质化合物能够促进核酸的吸收，特别是口服吸收，以及促进核酸进入有此需要的对象体内的靶部位。 | ||||||
| 10 | 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品 | CN201880023083.2 | 2018-03-29 | CN110520408B | 2022-11-25 | 蒋澄宇; 杜涧超; 梁竹; 李晓芸 |
| 本申请涉及从中药中提取多种能够促进核酸递送的化合物或合成的化合物，并利用所提取的化合物或多种组合促进核酸如sRNA吸收和进入靶细胞中，并能促进核酸进入有此需要的对象体内的靶部位。 | ||||||
| 11 | 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品 | CN201980023092.6 | 2019-03-28 | CN111918858A | 2020-11-10 | 蒋澄宇; 李晓芸; 杜涧超; 梁竹; 王志清; 王晨轩 |
| 涉及从中药中提取多种能够促进核酸递送的化合物或合成的化合物，并利用所提取的化合物或多种组合促进核酸如sRNA吸收和进入靶细胞中，并能促进核酸进入有此需要的对象体内的靶部位；所述中药选自红景天、蒲公英、穿心莲和金银花中药饮片；所述核酸用于治疗疾病，例如心脏、脾、肾、胃、肺和/或肠疾病。 | ||||||
| 12 | 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品 | CN201880023083.2 | 2018-03-29 | CN110520408A | 2019-11-29 | 蒋澄宇; 杜涧超; 梁竹; 李晓芸 |
| 本申请涉及从中药中提取多种能够促进核酸递送的化合物或合成的化合物，并利用所提取的化合物或多种组合促进核酸如sRNA吸收和进入靶细胞中，并能促进核酸进入有此需要的对象体内的靶部位。 | ||||||
| 13 | Novel fatty acid derivatives | JP2009141714 | 2009-06-12 | JP5232083B2 | 2013-07-10 | マイレン、フィン; ダレン、アレ; ビョレッツェン、ベルント; サンドボルド、マリット・リラント |
| 14 | Soft tertiary amine ester of bio-affecting carboxylic acid | JP686891 | 1991-01-24 | JPH0733719A | 1995-02-03 | KENESU BII SUROON |
| PURPOSE: To provide a novel compound which, when administered to warm- blooded animals, induces a bio-affecting response characteristic of the original acid from which the compound is derived and is less irritating and more excellent in permeability through a biological membrane than the parent compound. CONSTITUTION: There are provided a compound of formula I [wherein R-COO- is an acyloxy residue of a non-steroidal, anti-inflammatory and non-narcotic analgesic or antipyretic agent containing one carboxylic functional group, an acyloxy residue of a cephalosporin antibiotic containing one carboxylic functional group, an acyloxy residue of a penicillin antibiotic containing one carboxylic functional group, an acyloxy residue of a natural or synthetic amino acid containing one carboxylic functional group or the like; R 1 and R 2 are each alkyl, aryl, aralkyl or alkaryl; and R 3 is H, R 1', CO-R' 1, pyridyl (wherein R' 1 is phenyl, alkyl or the like)], a compound of formula II [wherein OOC-R'- COO is a di(acyloxy) residue of a bio-affecting dicarboxylic acid (e.g. methotrexate, penicillin and gultathione)] and acid addition salts and N-oxides thereof. COPYRIGHT: (C)1995,JPO | ||||||
| 15 | JPS4839409A - | JP9503972 | 1972-09-21 | JPS4839409A | 1973-06-09 | |
| 16 | Compound having acridan ring structure, and organic electroluminescent device | US14473025 | 2014-08-29 | US09818949B2 | 2017-11-14 | Norimasa Yokoyama; Makoto Nagaoka; Naoaki Kabasawa; Eiji Takahashi |
| An organic compound with characteristics excelling in hole-injecting/transporting performance and having an electron blocking ability, a highly stable thin-film state, and excellent heat resistance is provided as material for an organic electroluminescent device of high efficiency and high durability, and the organic electroluminescent device of high efficiency and high durability is provided using this compound. The compound of a general formula (Chemical Formula 1) having a substituted acridan ring structure is used as a constituent material of at least one organic layer in the organic electroluminescent device that includes a pair of electrodes and one or more organic layers sandwiched between the pair of electrodes. | ||||||
| 17 | Novel compounds and a novel process for their preparation | US10855783 | 2004-05-28 | US20050014721A1 | 2005-01-20 | Keith Fagnou; Mark Lautens |
| The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions. | ||||||
| 18 | Compositions and methods for treating mast-cell mediated conditions | US522157 | 1995-09-14 | US6022969A | 2000-02-08 | Ken Duane Rice; Jeffrey Mark Dener; Anthony Robert Gangloff; Elaine Yee-Lin Kuo |
| Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations. | ||||||
| 19 | Method for producing triarylorganoborates | US16348309 | 2017-11-07 | US11098066B2 | 2021-08-24 | Thomas Rölle; Horst Berneth; Dennis Hönel; Friedrich-Karl Bruder; Jürgen Kintrup |
| Provided herein is a process for preparing triaryl organoborates of the formula 1/n Kn+R34B−—R1 (IV), where one equivalent of organoboronic ester of the formula B—R1(OR2)(OR3) (I) is initially charged together with 1/n equivalents of salt Kn+ nX− (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1, 3 equivalents of a haloaromatic R4—Y (III) are added, an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n Kn+ R34B−—R1 (IV) is separated off with the organic phase, and to the use of these substances as co-initiator in photopolymer formulations. | ||||||
| 20 | Compound having acridan ring structure, and organic electroluminescent device | US13701940 | 2011-06-03 | US08852759B2 | 2014-10-07 | Norimasa Yokoyama; Makoto Nagaoka; Naoaki Kabasawa; Eiji Takahashi |
| An organic compound with characteristics excelling in hole-injecting/transporting performance and having an electron blocking ability, a highly stable thin-film state, and excellent heat resistance is provided as material for an organic electroluminescent device of high efficiency and high durability, and the organic electroluminescent device of high efficiency and high durability is provided using this compound. The compound of a general formula (Chemical Formula 1) having a substituted acridan ring structure is used as a constituent material of at least one organic layer in the organic electroluminescent device that includes a pair of electrodes and one or more organic layers sandwiched between the pair of electrodes. | ||||||
QQ群二维码
意见反馈
意见反馈